GC-MS analysis of Tasmannia lanceolata Extracts which Inhibit the Growth of the Pathogenic Bacterium Clostridium perfringens

Wright, Mitchell Henry; Lee, Cameron Jay; Arnold, Megan; Shalom, Joseph; White, Alan; Greene, Anthony Carlson; Cock, Ian Edwin

doi:10.5530/pj.2017.5.100

Cited by 13 publications

(22 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several marker compounds (polygodial, cineole, eugenol, linalool, terpineol) were selected as a comparison between the extracts as these have previously been reported to be present in relative abundance in T. lanceolata berry extracts. 8,9 All of these compounds were detected in both the solvent extract and in the supercritical fluid extract. The major peak in both extracts eluted at approximately 16.4 min.…”

Section: Non-targeted Gc-ms Headspace Analysis Of the T Lanceolata Ementioning

confidence: 98%

“…7 T. lanceolata extracts have even been reported to be effective inhibitors of the growth of the bacteria which cause anthrax (Bacillus anthricis) 8 and gas gangrene (Clostridium perfringens). 9 Both of these bacteria are endospore formers and are generally considered to be difficult to treat and decontaminate. The potential of T. lanceolata leaf extract in treating inflammation has also been reported.…”

Section: Introductionmentioning

confidence: 99%

“…8,9,11 These phytochemical evaluations have utilised LC-MS techniques to examine polar and mid-polarity compounds in leaf and berry extracts. 11 Similarly, the lower polarity compounds have been detected and identified using GC-MS techniques.…”

Section: Introductionmentioning

confidence: 99%

“…11 Similarly, the lower polarity compounds have been detected and identified using GC-MS techniques. 8,9 Irrespective of the technique used, a common feature of T. lanceolata composition is the high abundance of the sesquiterpenoid polygodial ( Figure 1a). Indeed, some studies report polygodial levels as high as may account for nearly 40% of some T. lanceolata preparations.…”

Section: Introductionmentioning

confidence: 99%

“…16 Further terpenoids including cineole (Figure 1b Figure 1e) have also been reported in relative abundance in T. lanceolata extracts. 8,9,16 Whilst conventional laboratory extraction has been useful in initial studies for screening T. lanceolata berries and leaves for therapeutic properties, upscaling the extraction to produce commercially relevant levels would use large amounts of expensive solvent and be time consuming to remove the solvents by drying. Furthermore, there are very real environmental pollution concerns associated with large scale usage of organic solvents.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

An upscaled extraction protocol for Tasmannia lanceolata (Poir.) A.C. Sm.: Anti-bacterial, anti-Giardial and anticancer activity

Vallette¹,

Rabadeaux²,

Sirdaarta³

et al. 2016

Self Cite

View full text Add to dashboard Cite

Background: Tasmannia lanceolata is an endemic Australian plant with a high anti-oxidant capacity. Liquid solvent extractions of T. lanceolata inhibit bacterial growth and block proliferation of several carcinomas and the gastrointestinal parasite Giardia duodenalis. Despite these promising therapeutic properties, methods for the rapid extraction of large quantities of T. lanceolata are lacking. This study aimed to develop a rapid supercritical extraction method to produce extracts which retain therapeutic propertyes and phytochemistry characteristics. Materials and Methods: T. lanceolata fruit and leaf were extracted by both solvent maceration extraction and supercritical fluid extraction (SFE). The extracts were tested for the ability to inhibit bacterial and G. duodenalis growth. Inhibition of CaCo2 and HeLa cancer cells was evaluated using MTS-based colorimetric cell proliferation assays. Toxicity was evaluated using an Artemia franciscana nauplii bioassay and GC-MS headspace analysis was used to evaluate phytochemical similarity between the extracts. Results: T. lanceolata berry and leaf SFEs displayed strong bacterial growth inhibitory activity against bacterial triggers of autoimmune inflammatory diseases, with efficacies similar to the smaller scale liquid solvent extractions. The growth inhibition of the berry SFE was particularly noteworthy against P. mirabilis and K. pneumoniae, with MIC values of approximately 160 and 190 µg/mL, respectively. The berry and leaf SFE extracts also had similar antiproliferative potencies against G. duodenalis (492 and 375 µg/mL, respectively), CaCo2 (4133 and 3347 µg/mL, respectively) and HeLa carcinomas (2652 and 3497 µg/mL, respectively) to those determined for the corresponding liquid solvent extractions. GC-MS analysis of the berry SFE revealed similar terpenoid components and similar abundances to those in liquid solvent berry extraction. Furthermore, all SFEs were either non-toxic or of only low toxicity in the Artemia franciscana toxicity assay. Conclusion: The T. lanceolata SFE retained the tested therapeutic properties, were nontoxic and had similar phytochemical profiles as smaller scale liquid solvent extractions. Thus, SFE is a viable method of rapidly extracting large masses of T. lanceolata plant material to produce quality extracts which retain therapeutic properties.

show abstract

Section: Non-targeted Gc-ms Headspace Analysis Of the T Lanceolata Ementioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%